Core Viewpoint - Vaxart, Inc. has officially withdrawn its reverse stock split proposal and will focus on advancing its oral recombinant vaccine platform to create long-term value for stockholders [1][2]. Company Overview - Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines using a proprietary delivery platform that allows for storage and shipping without refrigeration [3]. - The company's vaccine candidates include those targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [3]. - Vaxart has filed broad domestic and international patent applications for its oral vaccination technology [3].

Core Viewpoint - Vaxart, Inc. is advancing its oral vaccine platform and has appointed W. Mark Watson as Lead Independent Director to enhance governance and align board interests with stockholders [1][3] Company Developments - Vaxart is in the process of adopting a Director stock ownership policy to ensure alignment of interests between the Board and stockholders [3] - A special meeting of stockholders is scheduled for September 19, 2025, to discuss a reverse stock split proposal, with voting encouraged until September 18, 2025 [4][5] Leadership Background - W. Mark Watson brings over 50 years of experience, including significant roles at Deloitte and various biotech companies, and has been on Vaxart's Board since August 2022 [2] - Watson emphasizes the importance of regaining Nasdaq compliance for the company's long-term success [3] Vaccine Development - Vaxart is developing oral recombinant vaccines that can be stored without refrigeration, targeting diseases such as coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for HPV [6][7]

Core Points - Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant pill vaccines using its proprietary delivery platform [1][3] - The company will present at the H.C. Wainwright Global Investment Conference from September 8-10, 2025, with a specific presentation scheduled for September 8 at 12:00 PM ET [1][2] Company Overview - Vaxart's vaccines are designed to be administered in pill form, which can be stored and shipped without refrigeration, thus eliminating the risk of needle-stick injuries [3] - The company is developing oral vaccines for various diseases, including coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV) [3] - Vaxart has filed broad domestic and international patent applications for its proprietary technology related to oral vaccination using adenovirus and TLR3 agonists [3]

Core Viewpoint - Vaxart, Inc. has received approval from the Nasdaq Hearings Panel to implement a plan to regain compliance with Nasdaq's minimum bid price requirement, contingent upon completing a reverse stock split and demonstrating compliance by specified deadlines [1][2][5]. Group 1: Compliance Plan - The company must obtain stockholder approval for a reverse stock split by September 5, 2025, complete the reverse stock split by October 6, 2025, and demonstrate compliance with Nasdaq Listing Rule 5550(a)(2) by October 17, 2025 [2][3]. - Vaxart's management presented a compliance plan during a hearing on August 14, 2025, which included changes to the reverse stock split proposal, such as narrowing the proposed ratio and reducing the number of authorized shares [3]. Group 2: Stakeholder Engagement - The company is actively engaging with stockholders to address their questions and concerns, including a virtual fireside chat held on August 20, 2025 [4]. - CEO Steven Lo emphasized the importance of stockholder support for the reverse stock split to secure the company's future on Nasdaq [5]. Group 3: Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform, which allows for storage and shipping without refrigeration [7]. - The company's vaccine development programs include candidates for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [7].

Core Viewpoint - Vaxart, Inc. is seeking stockholder support for a reverse stock split proposal, which has been endorsed by leading proxy advisory firms ISS and Glass Lewis [1][3]. Group 1: Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [5]. - The company's vaccines are designed to be administered in pill form, eliminating the need for refrigeration and reducing the risk of needle-stick injuries [5]. - Current development programs include vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [5]. Group 2: Stockholder Engagement - The senior management team will host a virtual stockholder fireside chat on August 20, 2025, to address stockholder questions, particularly regarding the reverse stock split and Nasdaq compliance [2]. - Stockholders of record as of July 29, 2025, are encouraged to vote on the proposal by September 4, 2025 [4]. Group 3: Communication and Support - Investors can submit questions in advance of the conference call via email or through the webcast portal [3]. - A replay of the webcast will be available on the company's website after the event [3].

Core Insights - Vaxart, Inc. is set to release topline data from its norovirus Phase I trial on June 11, 2025, before market opening [1] - A live conference call will be held on the same day at 8:30 a.m. Eastern Time to discuss the data and provide updates on the trial [1][2] Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform [3] - The company's vaccines are designed to be administered in pill form, which can be stored and shipped without refrigeration, thus eliminating needle-stick injury risks [3] - Current development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [3] - Vaxart has filed broad domestic and international patent applications for its oral vaccination technology [3]

Core Insights - Vaxart, Inc. is participating in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025 [1] - The company is focused on developing oral recombinant vaccines that can be stored and shipped without refrigeration [3] Company Overview - Vaxart is a clinical-stage biotechnology company specializing in oral recombinant vaccines based on a proprietary delivery platform [3] - The company's vaccines aim to eliminate the risk of needle-stick injury and are designed for various diseases, including coronavirus, norovirus, influenza, and HPV [3] - Vaxart has filed broad domestic and international patent applications for its oral vaccination technology [3] Event Details - A live webcast of the fireside chat will be available on Vaxart's website, with a replay accessible for 30 days post-event [2] - Investors interested in meeting with Vaxart's management during the conference can contact their Jefferies representative [2]